Clinical trial results drove insider trading: SEC [Investment Executive - News]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Investment Executive - News
A biostatistician working for a U.S. pharmaceutical company used information about positive results in a cancer drug trial to engage in insider trading, U.S. authorities are alleging. In court filings, the U.S. Securities and Exchange Commission (SEC) alleged that Hong (John) Wang and his company, Precision Clinical Consulting LLC, engaged in insider trading involving the stock of a Massachusetts-based biopharmaceutical firm, C4 Therapeutics, Inc., based on data from its cancer drug trials. The SEC alleged that in 2023, as part of a consulting contract that required him to conduct biostatistical analysis on clinical trial data for the company's flagship drug for treating multiple myeloma and non-Hodgkin lymphoma, Wang learned of the trial's positive results, which weren't made public until mid-December 2023. Before that, it's alleged that Wang acquired more than 160,000 shares in the company across four different brokerage accounts, generating almost US$490,000 in realized and
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated PathwaysGlobeNewswire
- C4 Therapeutics (NASDAQ:CCCC) was given a new $5.00 price target on by analysts at Barclays PLC.MarketBeat
- C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.MarketBeat
- Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]Seeking Alpha
CCCC
Earnings
- 11/6/25 - Beat
CCCC
Sec Filings
- 1/16/26 - Form 4
- 1/14/26 - Form 8-K
- 1/5/26 - Form 4
- CCCC's page on the SEC website